Y Intercept Hong Kong Ltd Makes New Investment in Omnicell, Inc. $OMCL

Y Intercept Hong Kong Ltd bought a new stake in Omnicell, Inc. (NASDAQ:OMCL) in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 9,604 shares of the company’s stock, valued at approximately $282,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of OMCL. Victory Capital Management Inc. grew its stake in Omnicell by 10.1% during the 1st quarter. Victory Capital Management Inc. now owns 1,680,347 shares of the company’s stock valued at $58,745,000 after acquiring an additional 154,038 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. boosted its holdings in shares of Omnicell by 1.3% during the 2nd quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,423,604 shares of the company’s stock worth $41,854,000 after purchasing an additional 17,680 shares during the last quarter. Wellington Management Group LLP grew its position in shares of Omnicell by 52.6% in the first quarter. Wellington Management Group LLP now owns 496,680 shares of the company’s stock valued at $17,364,000 after purchasing an additional 171,116 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. grew its position in shares of Omnicell by 5.7% in the first quarter. Connor Clark & Lunn Investment Management Ltd. now owns 453,988 shares of the company’s stock valued at $15,871,000 after purchasing an additional 24,301 shares in the last quarter. Finally, Pacer Advisors Inc. acquired a new stake in shares of Omnicell in the first quarter valued at approximately $10,542,000. 97.70% of the stock is currently owned by institutional investors and hedge funds.

Omnicell Price Performance

Omnicell stock opened at $35.68 on Friday. The company’s 50 day simple moving average is $31.57 and its 200-day simple moving average is $30.35. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.24 and a current ratio of 1.42. Omnicell, Inc. has a 1 year low of $22.66 and a 1 year high of $52.90. The company has a market capitalization of $1.60 billion, a price-to-earnings ratio of 71.36, a price-to-earnings-growth ratio of 6.29 and a beta of 0.95.

Analysts Set New Price Targets

OMCL has been the topic of a number of recent research reports. Piper Sandler lowered their price objective on Omnicell from $57.00 to $55.00 and set an “overweight” rating on the stock in a research note on Monday, August 11th. Wells Fargo & Company lifted their price target on Omnicell from $37.00 to $40.00 and gave the stock an “overweight” rating in a report on Monday, July 21st. Wall Street Zen lowered shares of Omnicell from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 9th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Omnicell in a research note on Wednesday, October 8th. Finally, Benchmark increased their price target on shares of Omnicell from $40.00 to $45.00 and gave the company a “buy” rating in a research note on Friday, October 31st. Three analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $42.00.

Insider Buying and Selling

In other Omnicell news, EVP Corey J. Manley sold 3,880 shares of the company’s stock in a transaction on Friday, September 12th. The stock was sold at an average price of $33.25, for a total transaction of $129,010.00. Following the transaction, the executive vice president directly owned 110,653 shares in the company, valued at $3,679,212.25. This represents a 3.39% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 2.52% of the stock is owned by company insiders.

Omnicell Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.